2.32
3.57%
+0.08
After Hours:
2.3299
0.0099
+0.43%
Adial Pharmaceuticals Inc stock is currently priced at $2.32, with a 24-hour trading volume of 1.21M.
It has seen a +3.57% increased in the last 24 hours and a +46.84% rose in the past month.
The chart indicates a potential bearish trend, as the stock is below the $2.36 pivot point. If it approaches the $2.11 support level, significant changes may occur.
Adial Pharmaceuticals Inc Stock (ADIL) Financials Data
Adial Pharmaceuticals Inc (ADIL) Net Income 2024
ADIL net income (TTM) was -$6.07 million for the quarter ending September 30, 2023, a +61.33% increase year-over-year.
Adial Pharmaceuticals Inc (ADIL) Cash Flow 2024
ADIL recorded a free cash flow (TTM) of -$7.34 million for the quarter ending September 30, 2023, a +37.88% increase year-over-year.
Adial Pharmaceuticals Inc (ADIL) Earnings per Share 2024
ADIL earnings per share (TTM) was -$5.78 for the quarter ending September 30, 2023, a +66.45% growth year-over-year.
Adial Pharmaceuticals Inc Stock (ADIL) Insider Trading
Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
---|---|---|---|---|---|---|---|
Schuyler Kevin | Director |
Sep 29 '23 |
Buy |
2.74 |
700 |
1,918 |
700 |
Adial Pharmaceuticals Inc Stock (ADIL) Latest News
Why Ultragenyx Pharmaceutical Shares Are Trading Lower By Around 9%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Benzinga
Why JPMorgan Shares Are Trading Lower By Around 5%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Benzinga
Why NextPlat Shares Are Trading Higher By Around 30%; Here Are 20 Stocks Moving Premarket
Benzinga
Why Rallybio Shares Are Trading Higher By Around 78%; Here Are 20 Stocks Moving Premarket
Benzinga
S&P 500 Down 1%; Delta Air Lines Posts Upbeat Earnings
Benzinga
Why Ascent Solar Technologies Shares Are Trading Lower By Around 50%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Benzinga
About Adial Pharmaceuticals Inc
Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. Its lead product is AD04, a selective serotonin-3 antagonist, which is in Phase III clinical trial for the treatment of alcohol use disorder. The company also focuses on developing drug candidates for non-opioid pain reduction and other diseases and disorders. Adial Pharmaceuticals, Inc. was founded in 2010 and is based in Charlottesville, Virginia.
Cap:
|
Volume (24h):